Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: A 15-year retrospective, single center, cohort study

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1076-1082

  Shi, Hao ^a   Zhang, Wen ^a   Li, Xiao ^a   Ren, Hong ^a   Pan, Xiaoxia ^a   Chen, Nan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute kidney injury; Multiple myeloma; RIFLE criteria; Survival

Indexed keywords

BORTEZOMIB; CREATININE; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIFLE CRITERIA; SENESCENCE; STANDARD; TREATMENT RESPONSE; ACUTE KIDNEY INJURY; BIOPSY; CANCER STAGING; COMPLICATION; KIDNEY; MIDDLE AGED; MORTALITY; PATHOLOGY; PLASMAPHERESIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMAPHERESIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84899729571     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.820284     Document Type: Article

References (37)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc 2005; 80: 1371-1382.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005;55: 10-30.
4. Kyle RA, Therneau T M, Rajkumar S V, et al. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer 2004; 101: 2667-2674.
5. Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127: 299-304.
6. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
7. Kyle R A, Gertz M A, Witzig T E, et al. R eview of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
8. Bladé J, Ferná n dez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
9. Knudsen LM, Hippe E, Hjorth M, et al. Renal function in newly diagnosed multiple myeloma: A demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207-212.
10. Bellomo R, Ronco C, Kellum J A, et a l. A cute Dialysis Quality Initiative workgroup: Acute renal failure-defi nition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
11. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif 2010; 29: 300-307.
12. Stevens LA, Levey AS. Measured GFR as a confi rmatory test for estimated GFR. J Am Soc Nephrol 2009; 20: 2305-2313.
13. Schmitt R, Coca S, Kanbay M, et al CR. Recovery of kidney function after acute kidney injury in the elderly: A systematic review and meta-Analysis. Am J Kidney Dis 2008; 52: 262-271.
14. Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. QJM 1997; 90: 773-780.
15. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Greek Myeloma Study Group. Renal failure in multiple myeloma:incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337-341.
16. Prakash J, Niwas S S, Parekh A, et al. Multiple myeloma-presenting as acute kidney injury. J Assoc Physicians India 2009; 57: 23-26.
17. Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: A 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25: 419-426.
18. Matsue K, Fujiwara H, Iwama K, et al. Reversal of dialysisdependent renal failure in patients with advanced multiple myeloma: Single institutional experiences over 8 years. Ann Hematol 2010; 89: 291-297.
19. Christiansen CF, Johansen MB, Langeberg WJ, et al. Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study. Eur J Intern Med 2011; 22: 399-406.
20. U. S. Renal Data System, USRDS 2010 annual data report: Atlas of chronic kidney disease and end stage renal disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Healt h; 2010.
21. Kellum JA, Levin N, Bouman C, et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002; 8: 509-514.
22. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
23. Kellum JA, Bellomo R, Ronco C. Classification of acute kidney injury using RIFLE: What's the purpose? Crit Care Med 2007; 35: 1983-1984.
24. Ricci Z, Cruz DN, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008; 73: 538-546.
25. Bagshaw S M, George C, Dinu I, et a l. A Multi-center evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1203-1210.
26. Thakar CV, Christianson A, Freyberg R, et al. Incidence and outcomes of acute kidney injury in intensive care units: A Veterans Administration study. Crit Care Med 2009; 37: 2552-2558.
27. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
28. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN-Time for reappraisal. Crit Care 2009; 13: 211.
29. Ronco PM, Aucouturier P, Mougenot B. Monoclonal gammopathies: Multiple myeloma, amyloidosis and related disorders. In: Schrier RW, editor. Diseases of the kidney and urinary tract. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp 2205-2254.
30. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 2007; 109: 2604-2606.
31. Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010; 34: 1395-1397.
32. Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma: Plasmapheresis, hemodialysis and chemotherapy. Arch Intern Med 1990; 150: 863-869.
33. Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988; 33: 1175-1180.
34. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 2005; 143: 777-784.
35. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886-895.
36. Bridoux F, Fermand JP. Optimizing treatment strategies in myeloma cast nephropathy: Rationale for a randomized prospective trial. Adv Chronic Kidney Dis 2012; 19: 333-341.
37. Oyajobi B O. M ultiple myeloma/hypercalcemia. A rthritis Res Ther 2007; 9(Suppl. 1): S4.